Glybera's additional benefits not quantifiable, says Germany
This article was originally published in Scrip
The additional benefits of Chiesi/UniQure's orphan drug Glybera are not quantifiable, says the G-BA, the body in charge of Germany's AMNOG benefit assessments for new pharmaceuticals. The news comes after the G-BA last month slammed Chiesi for failing to properly disclose a potentially damming report from the European Medicines Agency.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.